Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study

• Published in: Scientific reports Vol. 11; no. 1; p. 17009
• Main Authors: Chen, Chao-Ping, Kung, Pei-Tseng, Chou, Wen-Yu, Tsai, Wen-Chen
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.08.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4023; 692/499; Antirheumatic Agents - pharmacology; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Autoimmune diseases; Biological products; Biological Products - pharmacology; Biological Products - therapeutic use; Cohort analysis; Cohort Studies; Humanities and Social Sciences; Humans; Middle Aged; multidisciplinary; Propensity Score; Proportional Hazards Models; Rheumatoid arthritis; Risk Factors; Science; Science (multidisciplinary); Thromboembolism; Venous Thromboembolism - etiology

In the United States, 100,000–300,000 patients die from venous thromboembolism (VTE) each year, with more than 500,000 people related hospitalizations. While in Europe, 500,000 people die from VTE each year. Patients with rheumatoid arthritis are at increased risk of VTE. The use of biologics in pat...